What is ImaCor?
ImaCor, Inc. operates at the intersection of critical care medicine and advanced diagnostic imaging. The company designs, manufactures, and distributes hTEE technology, which serves as a vital tool for clinicians tasked with optimizing cardiac performance throughout a patient's complex course of treatment. Unlike traditional diagnostic methods, ImaCor's hardware provides continuous, long-term hemodynamic monitoring, allowing for precise, data-driven interventions in high-acuity settings. This technological edge positions the firm as a key player in the evolving landscape of patient-centric cardiac care, where the demand for real-time physiological insights continues to grow among hospital systems and specialized surgical units.
How much funding has ImaCor raised?
ImaCor has raised a total of $5.5M across 2 funding rounds:
Series A
$5.5M
Debt
$79K
Series A (2009): $5.5M with participation from WFD VENTURES
Debt (2021): $79K led by PPP
Key Investors in ImaCor
WFD VENTURES
WFD Ventures LLC provides equity financing and industry expertise to medical device and healthcare technology companies, focusing on commercializing innovations that improve medical outcomes.
PPP
Public-Private Partnership
What's next for ImaCor?
With the recent influx of capital, ImaCor is poised to scale its commercial operations and broaden the adoption of its hTEE systems across global healthcare markets. The strategic roadmap likely involves enhancing manufacturing efficiencies and expanding the clinical evidence base to support wider integration into standard intensive care protocols. As the company transitions from its earlier growth phases into a more mature enterprise-level operation, the focus will remain on scaling distribution channels and refining its product suite to meet the rigorous demands of modern cardiology departments. Continued investment in research and development will be essential to maintaining its competitive advantage in the specialized medical device sector.
See full ImaCor company page
